JIANGXI BIO's Wholly-Owned Subsidiary Secures Regulatory Approval for Veterinary Tetanus Antitoxin

Stock News

13小時前

The company JIANGXI BIO (ASX: 06915) has announced that its wholly-owned subsidiary, Chifeng Boen Pharmaceutical Co., Ltd., has recently obtained the official approval document for its veterinary tetanus antitoxin product.

The veterinary tetanus antitoxin is primarily used for the prevention and treatment of tetanus infections in animals. It works by neutralizing the tetanus toxin, providing passive immunity to animals at risk of infection.

The board of directors believes that securing this approval further enriches the group's product portfolio. This development lays a foundation for the group's continued expansion in the animal health market and is expected to help enhance the group's overall competitiveness and long-term growth potential.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1131987482"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1131987482\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1131987482?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 06:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131987482","market":"other","top_or_hot":-1,"title":"JIANGXI BIO's Wholly-Owned Subsidiary Secures Regulatory Approval for Veterinary Tetanus Antitoxin","media":"Stock News","content":"<p>The company <b>JIANGXI BIO</b> (<b>ASX: 06915</b>) has announced that its wholly-owned subsidiary, Chifeng Boen Pharmaceutical Co., Ltd., has recently obtained the official approval document for its veterinary tetanus antitoxin product.<br><br>\nThe veterinary tetanus antitoxin is primarily used for the prevention and treatment of tetanus infections in animals. It works by neutralizing the tetanus toxin, providing passive immunity to animals at risk of infection.<br><br>\nThe board of directors believes that securing this approval further enriches the group's product portfolio. This development lays a foundation for the group's continued expansion in the animal health market and is expected to help enhance the group's overall competitiveness and long-term growth potential.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JIANGXI BIO's Wholly-Owned Subsidiary Secures Regulatory Approval for Veterinary Tetanus Antitoxin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJIANGXI BIO's Wholly-Owned Subsidiary Secures Regulatory Approval for Veterinary Tetanus Antitoxin\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-07-03 06:57</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>The company <b>JIANGXI BIO</b> (<b>ASX: 06915</b>) has announced that its wholly-owned subsidiary, Chifeng Boen Pharmaceutical Co., Ltd., has recently obtained the official approval document for its veterinary tetanus antitoxin product.<br><br>\nThe veterinary tetanus antitoxin is primarily used for the prevention and treatment of tetanus infections in animals. It works by neutralizing the tetanus toxin, providing passive immunity to animals at risk of infection.<br><br>\nThe board of directors believes that securing this approval further enriches the group's product portfolio. This development lays a foundation for the group's continued expansion in the animal health market and is expected to help enhance the group's overall competitiveness and long-term growth potential.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06915","symbol_name":"江西生物","start_time":0,"source_url":"","article_id":"1131987482","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131987482","pubTimestamp":1783033063,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"The company JIANGXI BIO (ASX: 06915) has announced that its wholly-owned subsidiary, Chifeng Boen Pharmaceutical Co., Ltd., has recently obtained the official approval document for its veterinary...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06915":"江西生物"},"translate_title":"江西生物全资子公司兽用破伤风抗毒素获监管批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06915":1},"content_text":"The company JIANGXI BIO (ASX: 06915) has announced that its wholly-owned subsidiary, Chifeng Boen Pharmaceutical Co., Ltd., has recently obtained the official approval document for its veterinary tetanus antitoxin product.\nThe veterinary tetanus antitoxin is primarily used for the prevention and treatment of tetanus infections in animals. It works by neutralizing the tetanus toxin, providing passive immunity to animals at risk of infection.\nThe board of directors believes that securing this approval further enriches the group's product portfolio. This development lays a foundation for the group's continued expansion in the animal health market and is expected to help enhance the group's overall competitiveness and long-term growth potential.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}